Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16335029rdf:typepubmed:Citationlld:pubmed
pubmed-article:16335029lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:16335029lifeskim:mentionsumls-concept:C0002892lld:lifeskim
pubmed-article:16335029lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:16335029lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:16335029lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:16335029pubmed:issue6lld:pubmed
pubmed-article:16335029pubmed:dateCreated2005-12-9lld:pubmed
pubmed-article:16335029pubmed:abstractTextPernicious anemia is the most frequent cause of megaloblastic anemia in our area, and it is the result of a vitamin B12 deficiency due, itself, to the decrease or absence of intrinsic factor (IF) because of gastric mucosa atrophy or autoimmune destruction of IF-producing parietal cells. With the existence of a severe gastric atrophy, there is a decrease in acid and IF production and a further change in vitamin B12 absorption. Fifty percent of the cases are associated to anti-IF antibodies, which presence in other autoimmune diseases is exceptional. In patients with pernicious anemia, measurement of anti-IF antibodies has high specificity (95%); however, measurement of anti-parietal cells antibodies has low specificity. The first-choice treatment is administration of vitamin B12 intramuscularly. The regimen is the administration of 1 mg of vitamin B12 daily for one week, weekly thereafter for one month and, then, every 2-3 months for life.lld:pubmed
pubmed-article:16335029pubmed:languagespalld:pubmed
pubmed-article:16335029pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16335029pubmed:citationSubsetIMlld:pubmed
pubmed-article:16335029pubmed:statusMEDLINElld:pubmed
pubmed-article:16335029pubmed:issn0212-1611lld:pubmed
pubmed-article:16335029pubmed:authorpubmed-author:Hernández-Nav...lld:pubmed
pubmed-article:16335029pubmed:authorpubmed-author:De PazRRlld:pubmed
pubmed-article:16335029pubmed:issnTypePrintlld:pubmed
pubmed-article:16335029pubmed:volume20lld:pubmed
pubmed-article:16335029pubmed:ownerNLMlld:pubmed
pubmed-article:16335029pubmed:authorsCompleteYlld:pubmed
pubmed-article:16335029pubmed:pagination433-5lld:pubmed
pubmed-article:16335029pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16335029pubmed:meshHeadingpubmed-meshheading:16335029...lld:pubmed
pubmed-article:16335029pubmed:meshHeadingpubmed-meshheading:16335029...lld:pubmed
pubmed-article:16335029pubmed:meshHeadingpubmed-meshheading:16335029...lld:pubmed
pubmed-article:16335029pubmed:articleTitle[Management, prevention and control of pernicious anemia].lld:pubmed
pubmed-article:16335029pubmed:affiliationServicio de Hematología y Hemoterapia Hospital Universitario La Paz Madrid. depazraquel@terra.eslld:pubmed
pubmed-article:16335029pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16335029pubmed:publicationTypeEnglish Abstractlld:pubmed